Colorectal Cancer

Optimal Treatment of Chemoresistant mCRC

Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.

In an interview with <em>Targeted Therapies in Oncology</em>, Michael Cusnir, MD, explained that Y-90 is a type of beta emitter that is extremely focused, which allows for the treatment to be localized without affecting healthy portions of the liver or other structures surrounding the liver; it is delivered to selectively embolize the liver.

The majority of younger patients ultimately diagnosed with colorectal cancer waited 3 to 12 months to see a doctor after symptoms began and were commonly misdiagnosed with&nbsp;issues such as hemorrhoids, irritable bowel syndrome, and anemia, according to recent findings.

A 75-Year-Old Man With Right-Sided mCRC

KRAS-Mutated Metastatic CRC

A small subset of patients with colorectal cancer benefited from the combination of nivolumab (Opdivo) and pixatimod (PG545), according to early results from a phase Ib trial.

Pashtoon M. Kasi, MD, MBBS, MS,&nbsp;provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape. &nbsp;<br /> &nbsp;

Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.

Axel Grothey, MD,&nbsp;discussed the results from a safety lead-in cohort to the BEACON CRC trial and highlighted the significance of these data.